SCHEDULE: BlackRock Discloses Verastem Stake

BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 7.0% of Verastem Inc.'s common stock as of June 30, 2026.

Summary

• BlackRock, Inc. has filed an amendment to its Schedule 13G filing.
• As of June 30, 2026, BlackRock beneficially owns 6,187,012 shares of Verastem Inc. common stock.
• This represents 7.0% of the total outstanding shares.
• BlackRock has sole voting power over 6,105,049 shares and sole dispositive power over 6,187,012 shares.
• The filing indicates that no single person has the right to receive or direct the sale of more than 5% of Verastem's common stock.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance updates for Verastem Inc.

Positives

• BlackRock, a significant institutional investor, holds a substantial stake in Verastem Inc.
• The filing confirms that BlackRock's ownership is in the ordinary course of business, suggesting a standard investment approach.

Risks

• Potential for future changes in BlackRock's ownership stake, which could impact share price and liquidity.
• The concentration of ownership, even if diversified across BlackRock entities, could influence corporate governance decisions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Verastem Inc. It pertains to BlackRock's ownership disclosure.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. BlackRock's filing indicates a significant but not controlling stake in Verastem, a biotechnology company.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant institutional holder, which can influence investor sentiment.
• Management: The disclosure confirms BlackRock's investment is in the ordinary course of business, not for control, which may be reassuring.

Next Steps

• BlackRock will continue to monitor its beneficial ownership of Verastem Inc. common stock.
• Future amendments to Schedule 13G will be filed if ownership levels change significantly.

Key Dates

Keywords

Verastem Inc., BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Securities Exchange Act